

Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/R25776BC9203EN.html>

Date: April 2022

Pages: 131

Price: US\$ 2,000.00 (Single User License)

ID: R25776BC9203EN

Abstracts

Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Drugs In Development, 2022, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Drugs In Development, 2022, provides comprehensive information on the

therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 19, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Rectal Cancer - Overview
- Rectal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rectal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rectal Cancer - Companies Involved in Therapeutics Development
- Rectal Cancer - Drug Profiles
- Rectal Cancer - Dormant Projects
- Rectal Cancer - Discontinued Products
- Rectal Cancer - Product Development Milestones
- Featured News & Press Releases
- Nov 12, 2021: Apexigen announces new phase 2 clinical data on CD40 antibody sotigalimab at the SITC 2021 Annual Meeting
- Feb 04, 2021: National Comprehensive Cancer Network provides updates on use of LONSURF (trifluridine and tipiracil) in NCCN Drugs and Biologics Compendium for colon cancer and rectal cancer
- Oct 22, 2018: NCCN awarded \$2 million in research funding from Taiho Oncology to study Trifluridine and Tipiracil in various cancers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rectal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Rectal Cancer - Pipeline by Advaxis Inc, 2022
Rectal Cancer - Pipeline by Alkermes Plc, 2022
Rectal Cancer - Pipeline by Amphivena Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Apexigen Inc, 2022
Rectal Cancer - Pipeline by AptaBio Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Arcus Biosciences Inc, 2022
Rectal Cancer - Pipeline by AstraZeneca Plc, 2022
Rectal Cancer - Pipeline by BeiGene Ltd, 2022
Rectal Cancer - Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
Rectal Cancer - Pipeline by BioAtla Inc, 2022
Rectal Cancer - Pipeline by Biomimetix JV LLC, 2022
Rectal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Rectal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Diverse Biotech Inc, 2022
Rectal Cancer - Pipeline by Eisai Co Ltd, 2022
Rectal Cancer - Pipeline by Eli Lilly and Co, 2022
Rectal Cancer - Pipeline by Ellipses Pharma Ltd, 2022
Rectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Rectal Cancer - Pipeline by Genentech USA Inc, 2022
Rectal Cancer - Pipeline by Genexine Inc, 2022

Rectal Cancer - Pipeline by Genome & Co, 2022
Rectal Cancer - Pipeline by GlaxoSmithKline Plc, 2022
Rectal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Rectal Cancer - Pipeline by Hutchison MediPharma Ltd, 2022
Rectal Cancer - Pipeline by Incyte Corp, 2022
Rectal Cancer - Pipeline by Innovent Biologics Inc, 2022
Rectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Rectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, 2022
Rectal Cancer - Pipeline by Merck & Co Inc, 2022
Rectal Cancer - Pipeline by Merck KGaA, 2022
Rectal Cancer - Pipeline by Millennium Pharmaceuticals Inc, 2022
Rectal Cancer - Pipeline by Novartis AG, 2022
Rectal Cancer - Pipeline by Oncolys BioPharma Inc, 2022
Rectal Cancer - Pipeline by OncXerna Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Rectal Cancer - Pipeline by Pieris Pharmaceuticals Inc, 2022
Rectal Cancer - Pipeline by Precigen Inc, 2022
Rectal Cancer - Pipeline by Privo Technologies Inc, 2022
Rectal Cancer - Pipeline by Sanofi, 2022
Rectal Cancer - Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Rectal Cancer - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Rectal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Rectal Cancer - Pipeline by Taiho Oncology Inc, 2022
Rectal Cancer - Pipeline by Teon Therapeutics Inc, 2022
Rectal Cancer - Dormant Projects, 2022
Rectal Cancer - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Rectal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R25776BC9203EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R25776BC9203EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

